Trials / Completed
CompletedNCT00171405
A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg
A 4 Month Extension to a 12 Month, Randomized, Open-label, Multicenter, Study to Assess the Long-term Safety of Aliskiren 150 mg Alone and 300 mg Alone or With the Optional Addition of Hydrochlorothiazide (12.5 mg or 25 mg) in Patients With Essential Hypertension
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 250 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to collect the long-term (12 months) safety data on aliskiren 300 mg when taken in combination with HCTZ 25 mg.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | aliskiren |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2006-02-01
- Completion
- 2006-02-01
- First posted
- 2005-09-15
- Last updated
- 2016-11-18
Locations
10 sites across 10 countries: United States, Belgium, Canada, Germany, Italy, Netherlands, Peru, Russia, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00171405. Inclusion in this directory is not an endorsement.